Immuron business update: letter to shareholders

Highlights: immuron board approves imm-529 cgmp manufacturing and to proceed with fda pre-ind submission recruitment and screening update for travelan® controlled human infection model (chim) clinical trial melbourne, australia, june 22, 2023 (globe newswire) -- immuron limited (asx: imc; nasdaq: imrn), an australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, is pleased to provide the following business update. dear immuron limited shareholders (asx: imc; nasdaq: imrn), immuron is pleased to announce that it has approved proceeding with imm-529 cgmp manufacturing and to proceed with fda pre-ind submission.
IMRN Ratings Summary
IMRN Quant Ranking